Haarberg H Eirik, Smalley Keiran S M
Drug Discov Today Technol. 2014 Mar;11:27-32. doi: 10.1016/j.ddtec.2013.12.004.
The use of small molecule BRAF inhibitors has revolutionized the treatment of advanced melanoma. Despite this, resistance is commonplace and associated with a median progression-free survival of >5 months. Major resistance mechanisms include reactivation of the MAPK pathway and increased PI3K/AKT signaling. Here we review some of the combination therapeutic strategies currently undergoing evaluation for the management of acquired drug resistance in melanoma.
小分子BRAF抑制剂的使用彻底改变了晚期黑色素瘤的治疗方式。尽管如此，耐药现象很常见，且与>5个月的中位无进展生存期相关。主要耐药机制包括MAPK通路的重新激活和PI3K/AKT信号传导增加。在此，我们综述了目前正在评估的一些联合治疗策略，用于管理黑色素瘤获得性耐药。
